Skip to main content
Fig. 4 | Acta Neuropathologica Communications

Fig. 4

From: Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group study

Fig. 4

Progression-free survival of all patients with Group 3/4 medulloblastomas stratified by presence of poor prognostic subtyping (a), whole chromosomal aberration (b), and MYC/N amplification (c). Progression-free survival of high-risk patients with Group 3/4 medulloblastomas stratified by presence of poor prognostic subtyping (d), whole chromosomal aberration (e), and MYC/N amplification (f)

Back to article page

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us